NEW YORK, Oct. 30, 2015 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that it has filed a class action lawsuit in the United States District Court for the District of New Jersey on behalf of all persons who purchased or otherwise acquired common stock of Valeant Pharmaceuticals International, Inc. (“Valeant” or the “Company”) (NYSE: VRX ) (TSX: VRX ) during the period February 22, 2015 through October 21, 2015, inclusive (the “Class Period"). A copy of the Complaint filed in this action can be viewed on the Wolf Haldenstein Adler Freeman & Herz LLP website at www.whafh.com .
If you purchased the shares of Valeant Pharmaceuticals International, Inc. during the period February 22, 2015 through October 21, 2015, inclusive, you may, no later than December 21, 2015, request that the Court appoint you lead plaintiff of the proposed class.
The Company is dually-listed in the United States and Canada. Shareholders who incurred losses on shares purchased on either the New York Stock Exchange or Toronto Stock Exchange within the Class Period are urged to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.
The complaint charges Valeant and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Valeant is a specialty pharmaceutical and medical device company that develops, manufactures, and markets a range of branded, generic, and branded generic pharmaceuticals, over-the-counter products, and medical devices, such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices.
The complaint alleges that during the Class Period, defendants made false and misleading statements and/or failed to disclose adverse information about the Company's business and prospects, including that the Company was using a network of specialty mail-order pharmacies that it actually controlled to prop up sales of its high-priced drugs and to keep patients and their insurance companies from switching to less costly generic drugs, that Valeant's undisclosed use of specialty pharmacies left it subject to increased regulatory risks, and that without the use of the specialty pharmacies, Valeant's financial performance and Class Period financial guidance would have been negatively impacted. As a result of these false and misleading statements and/or omissions, Valeant stock traded at artificially inflated prices during the Class Period, reaching over $260 per share.
Then on October 19, 2015, the Company issued a press release reporting its third quarter 2015 financial results. The same day, Valeant hosted an earnings call during which, for the first time, defendants revealed the previously undisclosed and direct relationship between Valeant and certain specialty pharmacies. On this news, the price of Valeant common stock fell over 10% in one day, from a close of $163.83 per share on October 19, 2015 to a close of $146.74 per share on October 20, 2015. Additional news concerning Valeant's unique relationships with specialty pharmacies reached the market on October 21, 2015, causing the price of Valeant stock to drop sharply, falling to a close of $118.61 per share, a 55% decline from the high of $263.81 reached on August 6, 2015.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions, please contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at classmember@whafh.com , or visit our website at www.whafh.com . All e-mail correspondence should make reference to “Valeant litigation.”
CONTACT: Contact: Wolf Haldenstein Adler Freeman & Herz LLP Kevin Cooper, Esq. or Gregory Stone Email: kcooper@whafh.com, gstone@whafh.com or classmember@whafh.com Tel: (800) 575-0735 or (212) 545-4774